BRNS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BRNS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Barinthus Biotherapeutics's Enterprise Value is $-52.64 Mil. Barinthus Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-62.09 Mil. Therefore, Barinthus Biotherapeutics's EV-to-FCF for today is 0.85.
The historical rank and industry rank for Barinthus Biotherapeutics's EV-to-FCF or its related term are showing as below:
During the past 5 years, the highest EV-to-FCF of Barinthus Biotherapeutics was 6.16. The lowest was -27.20. And the median was 0.66.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2025-03-02), Barinthus Biotherapeutics's stock price is $1.01. Barinthus Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.490. Therefore, Barinthus Biotherapeutics's PE Ratio (TTM) for today is At Loss.
The historical data trend for Barinthus Biotherapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
EV-to-FCF | - | - | -6.13 | 4.70 | -0.24 |
Barinthus Biotherapeutics Quarterly Data | |||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-FCF | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.58 | -0.24 | 0.39 | 0.91 | 0.74 |
For the Biotechnology subindustry, Barinthus Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's EV-to-FCF falls into.
Barinthus Biotherapeutics's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | -52.635 | / | -62.09 | |
= | 0.85 |
Barinthus Biotherapeutics's current Enterprise Value is $-52.64 Mil.
Barinthus Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (NAS:BRNS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Barinthus Biotherapeutics's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 1.01 | / | -1.490 | |
= | At Loss |
Barinthus Biotherapeutics's share price for today is $1.01.
Barinthus Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Barinthus Biotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Joseph Scheeren | director | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Robin Wright | director | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
William Enright | director, officer: Chief Executive Officer | 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878 |
Nadege Pelletier | officer: Chief Scientific Officer | C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF |
Gemma Brown | officer: Chief Financial Officer | VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF |
Graham Griffiths | officer: Chief Business Officer | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Christopher Ellis | officer: Chief Operating Officer | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Anne M. Phillips | director | C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406 |
Oxford Science Enterprises Plc | 10 percent owner | 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT |
Karen A Dawes | director | 579 BELLEVUE AVE, NEWPORT RI 02840 |
Pierre A. Morgon | director | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Margaret Marshall | officer: Chief Medical Officer | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Thomas George Evans | officer: Chief Scientific Officer | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Alex Hammacher | director | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
Georgy Egorov | officer: Chief Financial Officer | THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE |
From GuruFocus
By sperokesalga sperokesalga • 03-28-2023
By Marketwired • 01-10-2025
By sperokesalga sperokesalga • 06-21-2023
By Marketwired • 08-10-2023
By Marketwired • 11-15-2024
By Marketwired • 04-18-2024
By Marketwired • 11-15-2024
By Marketwired • 06-21-2023
By Stock market mentor Stock market mentor • 01-30-2023
By Marketwired • 08-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.